Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size

Newcastle Disease Virus (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Human / Clinical Studies

Table 2. Studies of NDV Oncolysates in Which Therapeutic Benefit Was Assesseda,b

Reference Citation(s)Type of StudyType of CancerNo. of Patients: Enrolled; Treated; ControlcStrongest Benefit ReporteddConcurrent TherapyeLevel of Evidence Scoref
No. = number.
a See text and theNCI Dictionary of Cancer Termsfor additional information and definition of terms.
b Oncolysates are prepared from virus-infected cancer cells; they consist primarily of cellmembranefragments and contain virusproteinsand cancer cell proteins.
c Number of patients treated plus number of patients control may not equal number of patients enrolled; number of patients enrolled = number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated = number of enrolled patients who were given the treatment being studiedAND for whom results were reported; historical control subjects are not included in number of patients enrolled.
d The strongest evidence reported that the treatment under study has anticancer activity or otherwise improves the well-being of cancer patients.
e Chemotherapy, radiation therapy,hormonal therapy, or cytokine therapy given/allowed at the same time as oncolysate treatment.
f For information about levels of evidence analysis and an explanation of the level of evidence scores, seeLevels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.
[1,2,4,11]Phase II trialAdvanced melanoma32; 32; Historical controlsImproved overall survivalNo3iiA
[1,2,11]Phase II trialAdvanced melanoma51; 51; Historical controlsImproved overall survivalNo3iiA
[6]Phase II trialAdvanced melanoma24; 24; Historical controlsNoneNo3iiDi
[5,7]Phase II trialMetastatic breast or ovarian22; 22; NoneComplete/partial tumor response, 9 patientsYes3iiDiii
[8,12]Phase II trialAdvanced renal cell208; 203; Historical controlsImproved disease-free survivalYes3iiiDi
[9,10]Phase I trialAdvanced melanoma13; 13; NoneComplete tumor response, 1 patientYes3iiiDii

Immunotherapy With Whole Cell Vaccines

The following information is summarized in a table located at the end of this section.

Most clinical studies of NDV-infected, whole cell vaccines that have been reported in scientific literature were conducted in Germany.[15,16,17,18,19,20,21,22,23,24,25,26,27,31,32] However, the largest reported trial was performed in China.[33] Reviewed in [14,34,35,36] Most of these studies involved patients with colorectal cancer,[15,16,19,20,22,33] breast cancer,[17,18,25] ovarian cancer,[17,18,23] renal cell cancer,[21,26] or malignant glioma.[31] The nonlytic strain NDV Ulster was used to prepare autologous tumor cell vaccines in all of the studies.

Data from a 2004 pilot clinical trial of an NDV-modified autologous tumor vaccine in 20 patients with stage III or IV head and neck squamous cell carcinomas suggest that the vaccine strategy can stimulate human antitumor immune responses in a manner similar to those found in animal models and may significantly prolong 5-year survival rates in this patient population. The study demonstrated the feasibility and safety of the vaccine regimen, and no major side effects were observed in any of the patients.[53]

1|2|3|4|5|6|7|8|9|10|11|12|13

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article